Skip to main content
. 2024 Dec 24;11:1464981. doi: 10.3389/fmed.2024.1464981

Figure 5.

Figure 5

(A–D) The probability of developing HCC after IPTW adjustment between GZ-B subgroup and immune tolerant group, HBeAg-positive immune activity, inactive group, and HBeAg-negative immune activation group (IPTW, inverse probability of treatment weighting; GZ, gray-zone).